Cardiac Embolism May Have Killed 13th Century Mummy: <\/strong>Italian researchers may have solved a 700-year-old medical mystery. It had previously been speculated that tuberculosis had been the cause of death of an 18- to 19-year-old girl who died in the 13th century and whose mummified remains have been preserved at the Santa Rosa monastery in Italy. But Ruggero D’Anastasio and colleagues found no evidence of chronic infectious disease. Instead, examination of the mummified chest and heart is consistent with Cantrell’s syndrome, and radiographic evidence of a mass between the apex of the left ventricle and the entry of the diverticulum suggests that the girl may have died of a cardiac embolism. The article appears in the Lancet<\/em><\/a>. Cardiac Embolism May Have Killed 13th Century Mummy: Italian researchers may have solved a 700-year-old medical mystery. It had previously been speculated that tuberculosis had been the cause of death of an 18- to 19-year-old girl who died in the 13th century and whose mummified remains have been preserved at the Santa Rosa monastery in […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1554","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1554"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1554\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n
\nBusy Summer at the FDA: <\/strong>In addition to the previously announced FDA advisory panel<\/a> for the ticagrelor (Brilanta, AstraZeneca) NDA on July 28, the FDA will hold an extraordinary 2-day advisory panel<\/a> to consider the fate of rosiglitazone (Avandia) on July 13 and 14. In addition, heartwire<\/em> reports<\/a>, but the FDA has not yet officially announced, that dabigatran (Pradax, Boehringer Ingelheim) will be reviewed on September 17. The FDA normally posts a detailed agenda, briefing materials, and the panel roster two days prior to the meeting.<\/p>\n","protected":false},"excerpt":{"rendered":"